These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 25398478

  • 1. The influence of secondary processing on the structural relaxation dynamics of fluticasone propionate.
    Depasquale R, Lee SL, Saluja B, Shur J, Price R.
    AAPS PharmSciTech; 2015 Jun; 16(3):589-600. PubMed ID: 25398478
    [Abstract] [Full Text] [Related]

  • 2. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS, Kim JH, Jin SG, Kim DW, Kim JO, Yong CS, Youn YS, Oh KT, Woo JS, Choi HG.
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 6. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D, Martin GP, Marriott C.
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [Abstract] [Full Text] [Related]

  • 7. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 9. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M, Ho S, Muddle J, Buttini F, Parry M, Hammond M, Forbes B.
    Int J Pharm; 2015 Jul 25; 490(1-2):360-7. PubMed ID: 25987210
    [Abstract] [Full Text] [Related]

  • 10. Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols.
    Zhang J, Khanal D, Chan HK, Banaszak Holl MM.
    Int J Pharm; 2024 May 10; 656():124116. PubMed ID: 38615803
    [Abstract] [Full Text] [Related]

  • 11. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA, Shur J, Ruecroft G, Hipkiss D, Price R.
    Int J Pharm; 2012 Jul 01; 430(1-2):26-33. PubMed ID: 22449413
    [Abstract] [Full Text] [Related]

  • 12. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
    Shur J, Saluja B, Lee S, Tibbatts J, Price R.
    AAPS J; 2015 Sep 01; 17(5):1105-16. PubMed ID: 25956383
    [Abstract] [Full Text] [Related]

  • 13. Quantitative Macro-Raman Spectroscopy on Microparticle-Based Pharmaceutical Dosage Forms.
    Wang H, Williams L, Hoe S, Lechuga-Ballesteros D, Vehring R.
    Appl Spectrosc; 2015 Jul 01; 69(7):823-33. PubMed ID: 26037516
    [Abstract] [Full Text] [Related]

  • 14. Optical photothermal infrared spectroscopy for nanochemical analysis of pharmaceutical dry powder aerosols.
    Khanal D, Kim J, Zhang J, Ke WR, Holl MMB, Chan HK.
    Int J Pharm; 2023 Feb 05; 632():122563. PubMed ID: 36586629
    [Abstract] [Full Text] [Related]

  • 15. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct 05; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT, Mehta R, Chan RH, Despa SX, Louey MD.
    J Aerosol Med Pulm Drug Deliv; 2014 Aug 05; 27(4):279-89. PubMed ID: 24074143
    [Abstract] [Full Text] [Related]

  • 17. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
    Tong HH, Shekunov BY, York P, Chow AH.
    J Pharm Sci; 2006 Jan 05; 95(1):228-33. PubMed ID: 16315225
    [Abstract] [Full Text] [Related]

  • 18. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
    Shur J, Kubavat HA, Ruecroft G, Hipkiss D, Price R.
    J Pharm Pharmacol; 2012 Sep 05; 64(9):1326-36. PubMed ID: 22881444
    [Abstract] [Full Text] [Related]

  • 19. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.
    Jaffari S, Forbes B, Collins E, Khoo J, Martin GP, Murnane D.
    Pharm Res; 2014 Dec 21; 31(12):3251-64. PubMed ID: 25015552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.